Fundraising Fox
Vyriad
Rochester, US · Delaware corporation · 3 known investors
Find your way into Vyriad
Sign up to see every warm intro you have to Vyriad
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vyriad team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vyriad is a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment. It works on engineering viral cancer immunotherapies and GMP virus manufacturing, and has pharma partnerships with companies including Novartis, Regeneron, and Merck KGaA.
Founders & leadership
SJ
Stephen J. Russell, MD, PhDCo-founder
KP
Kah-Whye Peng, PhDCo-founder
SJ
Stephen J. RussellExecutive Chairman and Chief Scientific Officer, Co-founder
LR
Luke RussellPresidentLuke Russell is President of Vyriad, a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment.
AS
Alice S. BexonChief Medical OfficerAlice S. Bexon is Chief Medical Officer at Vyriad, a clinical-stage biotech company developing oncolytic virus therapies for cancer. She brings experience in clinical development, regulatory strategy, and medical oversight across oncology, ophthalmology, infectious disease, and other therapeutic areas.
RA
Roger A. LindahlChief Financial OfficerChief Financial Officer of Vyriad, a clinical-stage biotechnology company developing oncolytic virus-based immunotherapies. Lindahl brings extensive financial leadership experience including monthly accounting close, financial reporting, GAAP and IFRS compliance, budgeting, and enterprise resource planning systems implementation.
JH
James HannonNamed on SEC filing
GN
Glen N. BarberNamed on SEC filing
AC
Ahryon ChoMember Board Of Directors2017–2021Regional Head, JLABS Korea at Johnson & Johnson Innovation – JJDC
AK
Andrew KhooNamed on SEC filing
NL
Nathan L. StacyNamed on SEC filing
Investors · 3
Also in the syndicate · 2
Stine Seed Farms Inc.leadStine Seed Farms, Inc.lead
Funding
SEC filings, press & company announcements$49.4M disclosed across 2 of 5 rounds · 2019–2026
- $25MSeries BJan 2026 · 2 sources
Stine Seed Farms Inc. (lead)
Source ↗ - Undisclosed amountSeries BDec 2025
Stine Seed Farms, Inc. (lead)
Source ↗ - Undisclosed amountSeries BMay 2022Source ↗
▶$24.4MraisedNov 2019 · 10 investors · BiotechnologyRule 506(b)
▶$24.4MraisedNov 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen J. Russell, MD, PhDExecutive Officer, Director, Promoter
- Kah-Whye Peng, PhDExecutive Officer
- James HannonExecutive Officer
- Glen N. BarberDirector, Promoter
- Ahryon ChoDirector
- Andrew KhooDirector
- Edwin M. Kania, Jr.Director
- Nathan L. StacyDirector
- Alice S. Bexon, MDExecutive Officer
- Offering amount
- $37.8M
- Amount sold
- $24.4M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Myriad GeneticsMyriad Genetics is a genetic testing and precision medicine company that delivers molecular diagnostic test results across hereditary cancer risk, reproductive health, oncology, urology, and mental health. It serves patients and healthcare providers with insights to help detect, treat, and prevent disease.
American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Fred HutchFred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.
Companies working in the same space as Vyriad.
In the news
Frequently asked questions
- What does Vyriad do?
- Vyriad is a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment. It works on engineering viral cancer immunotherapies and GMP virus manufacturing, and has pharma partnerships with companies including Novartis, Regeneron, and Merck KGaA.
- Who founded Vyriad?
- Vyriad was founded by Stephen J. Russell, MD, PhD, Kah-Whye Peng, PhD, Stephen J. Russell, Kah-Whye Peng.
- Who are Vyriad's investors?
- Vyriad's investors include Southeast Minnesota Capital Fund.
- How much funding has Vyriad raised?
- Vyriad has disclosed $49.4M raised across 2 of its 5 known rounds.
- Where is Vyriad headquartered?
- Vyriad is headquartered in Rochester, US.